BT

Bilal Tariq

Mutual Connections
Loading...
S9-052025-1314300

Send Message

No file chosen
1 Publications
0 Followers
0 Following
0 Questions

👤 About

Skills & Expertise

No skills added yet.

Research Interests

No research interests added yet.

Connect With Me

📚 Publications (1)

Journal: Leukemia & Lymphoma • December 2022
BTK inhibitor exposure increases significantly when coadministered with CYP3A inhibitors, which may lead to dose-related toxicities. This study explored the pharmacokinetics, efficacy, and safety of z...
Pharmacokinetics Cyp3a Ddi Btk Zanubrutinib
dd